Singapore-based AcroMeta Group Limited (SGX: 43F) has announced a strategic partnership with Macro HRD SG Pte. Ltd. (Macro HRD) to enter the ambient temperature cellular logistics (ATCLS) sector, a move that could transform the transportation of living cells and temperature-sensitive biological materials across Southeast Asia.
The non-binding term sheet outlines AcroMeta's acquisition of a strategic stake in Macro-ATCLS Pte. Ltd. (Macro-ATCLS), the commercialization vehicle for the ATCLS technology. Additionally, AcroMeta will hold an option to acquire an exclusive licence to deploy the technology across agreed territories in Southeast Asia, including the right to appoint sub-licensees. This exclusive arrangement is designed to give AcroMeta significant commercial reach in the region.
The ATCLS technology, licensed by Macro HRD, eliminates the reliance on conventional refrigerated and cryogenic cold chains. It uses proprietary ambient-temperature preservation and reactivation technologies, supported by the Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity, and process control. This enables dormant living cells to be transported at ambient temperature and reactivated at the point of use, addressing the fragility and geographic limitations of traditional cold-chain logistics.
The potential market is substantial. The global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035, a 25.1% compound annual growth rate. Underlying markets include immune-cell therapy (US$5.2 billion) and organ transplantation (US$47 billion). ATCLS estimates its serviceable addressable market (SAM) at approximately US$14.5 billion by 2032.
Lawrence Toh, Executive Director of AcroMeta, said, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we're excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
The partnership aligns with AcroMeta's growth strategy to evaluate strategic opportunities that support long-term shareholder value. The company, listed on the Catalist board of the Singapore Exchange since 2016, is primarily engaged in facility management services. This move diversifies its portfolio into a high-tech logistics niche.
Macro HRD, established in 2024, is a Singapore-based biotechnology and therapeutics company focusing on scalable precision-medicine solutions for infectious diseases. Its development portfolio includes innovative approaches targeting HIV/AIDS, HPV, and other enveloped viruses, supported by proprietary therapeutic and drug-delivery platforms. The ATCLS technology is a separate venture under Macro-ATCLS.
While the term sheet is non-binding, it sets the stage for definitive agreements. AcroMeta will conduct due diligence and negotiate final terms. The company emphasized disciplined capital allocation as it progresses through its next phase of development.
For more information about AcroMeta, visit www.AcroMeta.com. The original press release is available on NewMediaWire.
